Endocrine Abstracts

It has been established in recent years that androgens are involved in the progression of castration resistant prostate cancer (CRPC). Although androgen deprivation therapy reduces the level of androgens and inhibits the androgen receptor, there are studies reporting that the androgen signaling axis is still involved in the development of CRPC. We have in a previous study shown that low level of β2-adrenergic receptor (ADRB2) is associated with shorter time to ...